Trial Profile
An Open-Label, Randomised, Multi-Centre, Parallel Group Comparison of the Efficacy and Safety of Degarelix at Six Different Dosing Regimens in Patients With Prostate Cancer Treated for 12 Months [for extension study, see profile 700008605].
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 25 Aug 2011 New source identified and integrated (German Clinical Trials Register; DRKS00000024, UKF000001).
- 25 Aug 2011 New source identified and integrated (German Clinical Trials Register; DRKS00000024, UKF000001).
- 01 Apr 2009 Primary outcome amended as reported by ClinicalTrials.gov.